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Abstract 
We examined the in vivo effect of nicotine on the synthesis of (pro-)inflammatory mediators by mouse colonic mucosa. The 
synthesis of lipid mediators uch as the prostanoids prostaglandin E 2, 6-keto-prostaglandin Fl~~ and thromboxane B2, the 
5-1ipoxygenasc products leukotriene B4 and leukotriene C4 and the platelet activating factor was not affected, whereas the 
synthesis of the pro-inflammatory cytokines interleukin-1/3 and tumor necrosis factor a was completely abolished. The beneficial 
effects of smoking and nicotine in ulcerative colitis could be attributed to this inhibition. 
Keywords: Nicotine; Colonic mucosa; Cytokine 
During the last decade it has become clear that 
cigarette smoking not only increases the risk of devel- 
oping cancer or cardiovascular disease, but surpris- 
ingly, also has beneficial effects on acne (Mills et al., 
1993) and chronic diseases uch as Alzheimer disease 
(Jones et al., 1987) and ulcerative colitis (Rhodes and 
Thomas, 1994). The mechanisms underlying the benefi- 
cial effects are unknown. Nicotine is the most impor- 
tant pharmacologically active substance in tobacco 
smoke and it therefore seems logical to assume it to be 
responsible for most of the immunoregulatory effects 
of cigarette smoke. Treatment of patients with active 
ulcerative colitis with nicotine patches proved to have a 
beneficial effect. Symptoms significantly improved in 
these patients (Pullan et al., 19941. The effects of 
nicotine on lipid mediators uch as prostaglandins are 
still controversial. In rabbits prostaglandins were re- 
duced by nicotine, which showed an inverse dose de- 
pendence, whereas in ferrets no significant effects were 
observed (Zijlstra et al., 19941. 
This study was approved by the Animal Experimen- 
tal Committee of the Erasmus University of Rotterdam 
(protocol 118.94.17). Colonic mucosa was obtained from 
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BALB/c  female mice (19-21 g). Nine mice were used 
as controls, six mice were treated with nicotine. Ini- 
tially mice received nicotine in drinking water ad libi- 
turn: 2 days 25 /xg/ml, 2 days 50 /xg/ml, 2 days 100 
p~g/ml and 2 days 200 p.g/ml. Thereafter nicotine was 
dissolved in saline and given during 14 days subcuta- 
neously by an Alzet osmotic mini-pump with an infu- 
sion rate of 200 /xg/day. Controls received tap water 
and an osmotic pump filled with saline. Plasma nico- 
tine and cotinine concentrations reflected the dose of 
nicotine given and were measured by Dr. C. Feyer- 
abend, Nicotine Laboratory, Poisons Unit, New Cross 
Hospital London, UK. By the third week plasma nico- 
tine and cotinine concentrations were 3.6 + 0.61 and 
0.3 _+ 0.05 ng/ml  in controls and 42 _+ 3.0 and 105 _+ 11 
ng/ml  in nicotine treated mice respectively. These 
data were comparable to plasma levels of cotinine 
(102_+ 52 ng/ml)  in patients treated with nicotine 
patches with a release of 15 mg nicotine per day, 
reflecting 15 cigarettes per day (Pullan et al., 1994). 
After the mice were killed by cervical dislocation the 
colon from hepatic flexure to rectum was removed 
immediately. The colon was opened in a transverse 
direction and faeces was removed. The weight of the 
colon was determined and 2 ml Krebs-Henseleit buffer 
added, after which the tissue (approx. 200 rag) was 
fragmented using an Ultra-Turrax (Polytron, Switzer- 
land) and inflammatory mediators were measured. The 
amount of protein per mg wet homogenized tissue was 
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Table 1 
Formation of lipid mediators and cytokines by mouse colonic mucosa fter nicotine treatment 
Mediator Controls Nicotine 
Protein 
6-Keto-prostaglandin F1, ~ 
Prostaglandin E 2 
Thromboxane B 2 
Leukotriene B 4 
Leukotriene C 4 
Platelet activating factor 
Interleukin-I/3 
Tumor necrosis factor a 
(~g/mg) 
(pg/mg) 
(pg/rag) 
(pg/mg) 
(pg/mg) 
(pg/mg) 
(pg/mg) 
(pg/mg) 
(pg/mg) 
11.8_+ 0.69 12.5 ± 0.52 
3620 +_428 3500 +341 
1020 _+157 1170 ± 73 
416 _+ 53 415 ± 32 
3.4_+ 0.42 2.9± 0.28 
1.5± 0.27 1.8± 0.39 
54 + 20 48 ± 14 
1.3 ± 0.60 <0.1 ~ 
120 ± 58 13 ±13 a 
P < 0.05 compared with controls. 
determined by a micro-scale method (Instruchemie, 
Netherlands). Eicosanoids were determined by ra- 
dioimmunoassay, using antibodies from Advanced 
Magnetics (MA, USA), tritiated compounds from 
Amersham (UK) and standards from Sigma Co. (USA). 
Platelet activating factor was determined by radioim- 
munoassay (PAF-SPA system, Amersham, UK) and 
cytokines by enzyme-linked immunosorbent assay: tu- 
mor necrosis factor a from Genzyme Corp. (USA) and 
interleukin-1/3 from Cistron Biotechnology (Euro- 
genetics, Belgium). 
The synthesis of the lipid mediators was unaffected, 
whereas the production of pro-inflammatory c tokines 
was completely abolished (Table 1). 
This is, as far as we know, the first paper in which 
the direct effect of nicotine on the synthesis of pro-in- 
flammatory cytokines was investigated and shown to be 
of a strong inhibitory nature. Recently the effect of 
exposure to cigarette smoke was investigated in alveo- 
lar macrophages in rats (Pessina et al., 1993). As ex- 
pected tumor necrosis factor a was increased in alveo- 
lar macrophages, but surprisingly decreased in peri- 
toneal macrophages 8 h after the smoking session. In 
that study peritoneal macrophages were taken as inter- 
nal control cells and the authors failed to conclude that 
this unexpected effect could be due to circulating nico- 
tine. 
Both tumor necrosis factor a and interleukin-1/3 are 
thought o be the most important cytokines involved in 
the initial events preceding the further development of
inflammation i  the bowel. Although tumor necrosis 
factor a and interleukin-1/3 are mainly produced by 
macrophages (Pruimboom et al., 1994), other cells also 
secrete tumor necrosis factor a. It was clearly shown 
that tumor necrosis factor a secreting cells are in- 
creased in the mucosa of inflamed intestine (Breese et 
al., 1994). 
Our results offer a possible explanation for the 
beneficial effects of nicotine in ulcerative colitis. 
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